Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PUMA BIOTECHNOLOGY, INC.

(PBYI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Puma Biotechnology : Expands Common Share Issuance Under Incentive Stock Options by 2 Million

06/17/2021 | 06:22am EDT


ę MT Newswires 2021
All news about PUMA BIOTECHNOLOGY, INC.
04:35pPUMA BIOTECHNOLOGY : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION..
AQ
04:21pPUMA BIOTECHNOLOGY : Reports Second Quarter 2021 Financial Results
BU
04:20pPUMA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financ..
AQ
04:10pPUMA BIOTECHNOLOGY : Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Reports Q2 EPS $0...
MT
04:09pPUMA BIOTECHNOLOGY : Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q2 Revenue $..
MT
12:15pEARNINGS REACTION HISTORY : Puma Biotech Inc, 60.0% Follow-Through Indicator, 16..
MT
07/29PUMA BIOTECHNOLOGY : Note Purchase Agreement (Form 8-K)
PU
07/29PUMA BIOTECHNOLOGY, INC. : Entry into a Material Definitive Agreement, Creation ..
AQ
07/26PUMA BIOTECHNOLOGY : Secures $125 Million Note Purchase by Athyrium Capital
BU
07/23Puma Biotechnology, Inc. announced that it expects to receive $125 million in..
CI
More news
Financials (USD)
Sales 2021 266 M - -
Net income 2021 5,07 M - -
Net cash 2021 37,8 M - -
P/E ratio 2021 -200x
Yield 2021 -
Capitalization 282 M 282 M -
EV / Sales 2021 0,92x
EV / Sales 2022 0,76x
Nbr of Employees 267
Free-Float 86,4%
Chart PUMA BIOTECHNOLOGY, INC.
Duration : Period :
Puma Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PUMA BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Last Close Price 6,99 $
Average target price 10,38 $
Spread / Average Target 48,4%
EPS Revisions
Managers and Directors
Alan H. Auerbach Chairman, President, CEO & Secretary
Maximo F. Nougues Chief Financial Officer
Jay M. Moyes Lead Independent Director
Troy E. Wilson Independent Director
Adrian M. Senderowicz Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PUMA BIOTECHNOLOGY, INC.-33.24%276
MODERNA, INC.301.12%168 260
LONZA GROUP AG26.76%59 023
IQVIA HOLDINGS INC.39.45%47 876
CELLTRION, INC.-25.07%32 166
SEAGEN INC.-6.81%29 694